Veracyte
Veracyte is a genomic diagnostics company focused on resolving diagnostic uncertainty and guiding care in selected disease areas. Its platform includes genomic classifiers and molecular tests used in fields such as thyroid cancer, prostate cancer, breast cancer, lung cancer, and interstitial lung disease.
- Highest 2026 tier: Tier II
- Genetic Testing & Genomics Providers
- 2 ranking categories
Overview
Veracyte is a genomic diagnostics company focused on resolving diagnostic uncertainty and guiding care in selected disease areas. Its platform includes genomic classifiers and molecular tests used in fields such as thyroid cancer, prostate cancer, breast cancer, lung cancer, and interstitial lung disease.
The company’s importance lies in clinical decision support. Some genetic and genomic tests are not broad sequencing panels but disease-specific classifiers designed to clarify whether surgery, biopsy, surveillance, or treatment is appropriate. This type of genomic diagnostic can influence care pathways even when it is narrower than comprehensive genomic profiling.
Veracyte is included in 2 2026 ranking categories. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Veracyte |
| Founded | 2008 |
| Institution type | Genetic Testing & Genomics Providers institution |
| Headquarters | South San Francisco, United States |
| Primary focus | Genetic Testing & Genomics Providers |
| Highest 2026 ranking tier | Tier II |
Principal activities
The company’s importance lies in clinical decision support. Some genetic and genomic tests are not broad sequencing panels but disease-specific classifiers designed to clarify whether surgery, biopsy, surveillance, or treatment is appropriate. This type of genomic diagnostic can influence care pathways even when it is narrower than comprehensive genomic profiling.
Core capability
Genetic Testing & Genomics Providers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Genetic Testing & Genomics Providers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Veracyte’s focused test portfolio, clinical utility orientation, and role in specialty decision-making support its inclusion among established genetic testing and genomics providers.
Veracyte is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Veracyte should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Veracyte. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Veracyte |
| Headquarters | South San Francisco, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Genetic Testing & Genomics Providers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Precision Medicine Diagnostics Providers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
